Nevir-ER (nevirapine) is a synthetic antiviral drug from the group of non-nucleoside reverse transcriptase inhibitors for oral administration.
Nevirapine is a synthetic antiviral drug from the group of non-nucleoside reverse transcriptase inhibitors. The mechanism of action of the drug consists in binding with the enzyme of the HIV-1 virus – reverse transcriptase and blocking the activity of DNA polymerase by destroying the catalytic part of the enzyme. Nevirapine is active exclusively against the human immunodeficiency virus type I and is inactive against the HIV-2 virus and human α-, β- and γ-DNA polymerase.
When taken orally, nevirapine is rapidly absorbed, the maximum concentration in the blood is reached within 4 hours. Bioavailability is 93%. Nevirapine binds well to blood plasma proteins. The drug penetrates well through the blood-brain barrier. Nevirapine crosses the placental barrier and is excreted in breast milk. The drug is metabolized in the liver, excreted from the body mainly by the kidneys in the form of inactive metabolites, partially excreted in the feces. The half-life of nevirapine is 25-30 hours, this time does not change in hepatic and renal failure.